Latest news with #DSCSA
Time Business News
22-05-2025
- Business
- Time Business News
Pharma Distributors and the Challenge of Counterfeit Drugs: Prevention and Solutions
Counterfeit drugs have become a grave concern in the pharmaceutical industry. They pose severe risks to patient safety and can undermine the trust in healthcare systems. Combating counterfeit drugs is a significant challenge for pharmaceutical wholesalers that require vigilance and advanced strategies. Read on to understand the various complexities associated with counterfeit drugs encountered by pharmaceutical wholesalers. The global nature of drug manufacturing and distribution makes it hard to track every product. Counterfeit drugs can slip into the supply chain at multiple points, which makes them difficult to detect. Oftentimes, pharmaceutical supply chains lack transparency. This opacity can create opportunities for counterfeiters to introduce fake products undetected. Medications in high demand and low supply are prime targets for counterfeiters. Hence, wholesalers need to be extra vigilant with these high-risk drugs. Here's how pharmaceutical wholesalers can prevent the counterfeit drug Implementing digital tracking systems, like blockchain technology, can enhance supply chain transparency. Tracking each drug package from manufacture to delivery can reduce the chances of counterfeits. Using tamper-evident packaging can help identify compromised products. Wholesalers should work with manufacturers to ensure all packaging includes anti-counterfeit measures. Collaborations and Data Sharing Collaborating with other stakeholders in the supply chain, including manufacturers, regulators, and pharmacies, can improve data sharing and collective vigilance against counterfeit drugs. Staying compliant with local and international regulations can help wholesalers monitor and prevent counterfeit drugs. Regular audits and inspections ensure all processes are up to standard. Drugzone, one of the top pharmaceutical distributors in the U.S., strictly follows the rules set by the Drug Supply Chain Security Act (DSCSA). This means they use advanced tracking technologies besides other measures to keep a close eye on every medication they distribute. Counterfeit drugs are fake medications that may contain incorrect or harmful ingredients. They pose serious risks to patient health and safety. TIME BUSINESS NEWS
Yahoo
14-05-2025
- Business
- Yahoo
Fusion Partners with MMCAP to Offer Advanced DSCSA Compliance Solution, Fusion360, to Government Healthcare Facilities Nationwide
WOODBRIDGE, N.J., May 13, 2025 /PRNewswire/ -- Fusion Health, a leading provider of health technology solutions for public health settings, today announced a new agreement with MMCAP, a national cooperative purchasing organization. This partnership will provide MMCAP members streamlined access to, and negotiated pricing for, Fusion360—Fusion Health's comprehensive DSCSA (Drug Supply Chain Security Act) compliance management solution. Through this agreement, MMCAP's extensive network of over 26,000 members—spanning state agencies, counties, cities, and school districts across all 50 states—will have streamlined access to Fusion360. This powerful software solution is designed to help pharmacies and healthcare systems efficiently meet federal DSCSA requirements, enhance pharmaceutical supply chain integrity, and ensure patient safety by simplifying traceability, verification, and reporting processes for prescription medications. "We are thrilled to collaborate with MMCAP and empower their members with Fusion360, our leading-edge DSCSA compliance solution," said Michael Jakovcic, CRO, Fusion. "This partnership underscores our commitment to providing pharmacies across the country with the critical tools they need for operational excellence." Fusion360 helps organizations automate DSCSA compliance tasks, reduce the risk of counterfeit or illegitimate products entering the supply chain, and maintain audit-readiness. This ensures that MMCAP members can confidently manage their pharmaceutical operations while focusing on patient care. Fusion360 is a key component of Fusion's broader mission to support these essential organizations. Beyond DSCSA compliance, Fusion Health offers a comprehensive suite of integrated solutions, including our robust electronic health record platform (FusionEHR), specialized 340B management software, comprehensive retail and inpatient pharmacy management systems, and our innovative Fusion Financials solution designed to streamline revenue cycle management and billing services. Together, these offerings help our partners enhance care delivery, improve efficiency, and navigate complex regulatory landscapes. Learn more about Fusion Health's solutions for government and public health facilities at About Fusion Health Fusion Health equips providers in public safety agencies, behavioral health settings, educational institutions, and other governmental organizations with an ecosystem of solutions they can use to work faster, smarter, and more efficiently to deliver highly effective care to patients. We offer a portfolio of innovative, market-leading healthtech products that assist clinicians in making care decisions and aid organizations in managing the health of their populations. Fusion Health's clinical technologies connect people with information systems at thousands of facilities nationwide, driven by a vision of a future where our products contribute to a ripple effect of positive change within the broader public health landscape—a landscape where every individual, regardless of circumstance, has access to quality care. Learn more at Media Contact: Jerry Kimbrough, View original content to download multimedia: SOURCE Fusion Health
Miami Herald
08-05-2025
- Business
- Miami Herald
CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops
The correction is to the headline only TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network. "At Wellgistics Health, we challenge the idea that healthcare has to be tethered to legacy systems, bloated intermediaries, and slow-moving money," said Brian Norton, CEO of Wellgistics Health. "We are developing a platform that connects manufacturers directly to pharmacies and patients-bypassing the red tape and placing control back in the hands of those who deliver care. Our blockchain-enabled payment system and ledger is just the next logical step in healthcare evolution, allowing us to hardwire speed, liquidity, and transparency into a system that's long been starved of all three. I believe that the future winners in healthcare won't be the companies with the biggest buildings…they'll be those with the fastest rails, cleanest data, and most efficient platforms. We're betting on infrastructure…not inertia." Why XRP? Why Now? We believe that there are certain advantages to integrating XRP and its related infrastructure into its healthcare ecosystem. These include, among others: Speed: XRP settles transactions in 3-5 seconds vs. 1-3 days for ACH or wire transfers, allowing for near real-time settlement among pharmacies, suppliers, and Less than $0.0002 per transfer vs. $10-$30 for standard bank All transactions are logged on the XRP Ledger for real-time compliance, rebate tracking, and Supports global vendor payouts with significantly low foreign exchange and wire transfer Allows for XRP-backed lines of credit to support independent pharmacy liquidity. These benefits will support faster vendor payments, performance-based rebates, and embedded liquidity tools for pharmacies and manufacturers in the Wellgistics ecosystem. Use Cases Across the Ecosystem Real-time settlement between pharmacies, suppliers, and manufacturersSmart rebates calculated automatically based on real-world dataXRP-backed credit lines to enhance liquidity for independent pharmaciesGlobal vendor payouts with near-zero foreign transaction and wire costsImmutable compliance layer supporting DSCSA reporting and pricing validation "We're working to unlock capital velocity with surgical precision," said Mark DiSiena, CFO of Wellgistics Health. "We believe that our XRP-powered infrastructure will allow us to run leaner, faster, and with more control than any of our peers in pharma infrastructure." The Market Is Moving-And Wellgistics Intends to Lead XRP is gaining momentum across global institutions, as demonstrated by the following: CME Group to launch XRP futures for institutional access→ CME will launch cash-settled XRP futures contracts in May 2025 to meet rising institutional demand.¹Mastercard identifies XRP as a bridge currency for cross-border payments→ Mastercard's 2025 report highlights XRP as a top solution for global remittances and cost efficiency.²Ripple acquires prime brokerage firm Hidden Road for $1.25B→ This landmark acquisition expands XRP's footprint in institutional liquidity and asset servicing.³Ripple receives regulatory licensing in Dubai→ Ripple became the first blockchain payment provider licensed by the DFSA to operate crypto-based financial services in the UAE.⁴Ripple expands real-world cross-border payment corridors in Brazil and Portugal→ Ripple now enables live XRP-powered remittances between LATAM and Europe through its partnership with Unicâmbio.⁵ "Others are waiting for change. We're building it," Norton added. "I strongly believe that our XRP initiative positions Wellgistics Health years ahead of the curve-and squarely at the center of where healthcare and fintech converge." About Wellgistics Health Wellgistics Health, Inc. (NASDAQ:WGRX) is a publicly traded healthcare infrastructure company transforming how medications move, get priced, and reach patients. The company operates across pharmaceutical distribution, prescription technology, and clinical fulfillment-connecting over 150 direct manufacturer contracts to a growing network of more than 6,000 independent pharmacies nationwide. Wellgistics Health delivers real-time prescription hub services, compliance-driven logistics, and patient-first fulfillment models, while equipping pharmacies with embedded financial, clinical, and digital tools. Its integrated platform supports a wide range of therapeutic categories-from specialty-lite to maintenance meds-by eliminating friction, accelerating reimbursements, and creating direct, transparent pathways between manufacturers, providers, pharmacies, and patients. For more information, visit: Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at Media Contact: media@ Relations: investors@ References CME Group Press Release: CME to Launch XRP FuturesAInvest: Mastercard Identifies XRP as Bridge CurrencyReuters: Ripple Acquires Hidden Road for $1.25BBusinessWire: Ripple Licensed by DFSA in DubaiPYMNTS: Ripple Launches Portugal-Brazil Corridor SOURCE: Wellgistics Health, Inc.
Cision Canada
06-05-2025
- Business
- Cision Canada
FutureLink Boston 2025 Reinforces TraceLink's Leadership in Supply Chain Orchestration and Innovation
BOSTON, May 6, 2025 /CNW/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, successfully hosted FutureLink Boston 2025, bringing together more than 150 attendees ranging across senior executives, industry experts, and supply chain technology innovators from across the end-to-end healthcare and life sciences ecosystem. Now in its ninth year, FutureLink remains the only industry event focused exclusively on safeguarding and advancing the digital transformation of the end-to-end life sciences and healthcare supply chain. With an agenda specifically designed to bridge the gap between strategic vision and operational execution, FutureLink Boston offered a unique opportunity for attendees to gain direct insight from the companies shaping the future of life sciences and healthcare. Over three days, attendees explored how digitalization, real-time supply and demand data, and generative AI are transforming supply chain operations and delivering meaningful impact to patients worldwide. "With representation from every corner of the supply chain, FutureLink is unmatched in its ability to bring the healthcare and life sciences industry together to transform vision into action," said Shabbir Dahod, President and CEO of TraceLink. "It's the only forum where innovation at the intersection of supply chain digitalization, regulatory readiness, and agentic orchestration converge to drive measurable impact—all powered by an integrate-once digital business network that doesn't exist anywhere else in the world. That network is the foundation for building intelligent, linked, and patient-centric supply chains, and FutureLink is one of the ways we bring that leadership to life." Driving Digital Transformation Across the Industry With 26 industry speakers and nearly 50 total sessions, the event showcased how customers are using the TraceLink Orchestration Platform for Universal Solutions (OPUS) to orchestrate supply chain relationships, digitalize critical business processes, and supply generative AI models and enterprise systems with real-time supply chain data. A special focus was placed on: Leveraging DSCSA and serialization investments as a foundation for digital transformation. Ensuring DSCSA readiness among more than 5,000 companies and 650 TraceLink DSCSA customers already deploying more than 10,000 EPCIS links. Using TraceLink Multienterprise Information Network Tower (MINT) to exchange more than 40 commercial transactions, including purchase orders, inventory balances, advanced ship notices, and invoices, to build intelligent orchestration layers on existing track-and-trace infrastructure. The need for collaborative trading partner execution for critical processes such as DSCSA compliance exception management through solutions like TraceLink Process Orchestration for Empowered Teams (POET). Fueling generative AI initiatives with foundational, real-time supply chain data to create agentic orchestration experiences. Leveraging the open OPUS service, solution, and technology partner ecosystem for digital transformation acceleration, as evidenced by the presence of 19 different solution and technology partner companies at the conference. FutureLink Boston set the stage for what's next in global supply chain transformation. This fall, the momentum continues in Europe. Registration is now open for FutureLink Barcelona— join us October 6-8, 2025 to collaborate with industry leaders, explore breakthrough innovations, and accelerate your journey toward a more agile, intelligent, and patient-centric supply chain. About TraceLink TraceLink Inc. is the largest end-to-end intelligent supply chain platform for life sciences and healthcare, enabling end-to-end orchestration by connecting more than 291,000 healthcare and life sciences entities through its B2N Integrate-Once™ network. Leading businesses trust TraceLink to deliver complete global connectivity, visibility, and traceability of healthcare products, ensuring that every patient gets the medicines they need when needed, safely and securely.
Yahoo
09-04-2025
- Business
- Yahoo
MMCAP Infuse Expands Inmar Agreement, Deploying OneRecall® for Smarter Recalls
MMCAP Infuse members gain automated tools to meet DSCSA requirements and safeguard patient safety WINSTON-SALEM, N.C., April 9, 2025 /PRNewswire/ -- Inmar Intelligence, a leader in healthcare logistics and compliance solutions, has announced the renewal and expansion of its contract with MMCAP Infuse through a multi-year agreement. This renewed contract extends access to Inmar's comprehensive healthcare solutions while introducing OneRecall®, an advanced recall management system designed to streamline workflows and reduce alert fatigue for healthcare providers. As a national cooperative group purchasing organization (GPO), MMCAP Infuse supports over 34,500 member facilities, including state agencies, counties, cities, school districts, public health facilities, and educational institutions. GPOs like MMCAP Infuse play a critical role in helping their members navigate complex regulatory landscapes, including compliance with the Drug Supply Chain Security Act (DSCSA). However, ensuring full compliance presents operational and logistical challenges, such as standardizing product tracking, managing large networks of suppliers, and implementing efficient recall protocols. With the expansion of this partnership, MMCAP Infuse members will now have direct access to OneRecall®, a solution designed to help address these challenges and enhance regulatory adherence. Beyond recall management, Inmar has long provided MMCAP Infuse with a suite of healthcare solutions that enhance operational efficiency, regulatory compliance, and patient safety across its diverse membership. From pharmaceutical returns management to supply chain visibility tools, Inmar helps MMCAP Infuse members reduce waste, optimize inventory, and ensure compliance with evolving industry regulations. With this contract renewal, MMCAP Infuse members continue to benefit from Inmar's expertise in streamlining purchasing processes, automating compliance workflows, and enhancing financial and operational transparency. With MMCAP Infuse members preparing for full DSCSA implementation, ensuring compliance while managing complex recall processes is a top priority. Under the renewed agreement, Inmar's OneRecall® solution will help MMCAP Infuse members meet DSCSA requirements by automating recall notifications, reducing manual tracking, and minimizing administrative burdens. OneRecall® enables members to prioritize high-risk recalls, respond quickly, and maintain regulatory compliance without disrupting patient care. Beyond DSCSA compliance, MMCAP Infuse must support a diverse network of government healthcare facilities while maintaining operational efficiency. Managing large-scale purchasing agreements across thousands of member sites requires seamless coordination, real-time data tracking, and proactive compliance support. Inmar's long-standing agreement with MMCAP Infuse provides integrated solutions that simplify these processes, offering advanced tools for recall management, regulatory reporting, and inventory optimization. The expansion of OneRecall® further enhances MMCAP Infuse members' ability to improve data accuracy, reduce administrative overhead, and strengthen compliance training. "This expanded agreement reinforces our commitment to equipping MMCAP Infuse members with the tools they need to remain compliant, operate efficiently, and focus on delivering quality healthcare," said Brian Nightengale, EVP, Healthcare at Inmar Intelligence. "By integrating OneRecall® into their workflow, we are not only improving recall responsiveness but also supporting broader supply chain security initiatives." About Inmar IntelligenceThrough curiosity and the intelligent use of data and technology, we optimize the healthcare value chain to improve patient safety, access and affordability. As a partner for over 40 years to health systems, pharmacies and life sciences companies, we design and build solutions to address the complex challenges in the business of healthcare. Our mission is to enable improved financial and patient outcomes to meet the evolving needs of the healthcare industry. Visit and follow us on LinkedIn. Email us at solutions@ or call (866) 440-6917. Media Contact: Lari Harding, Senior Vice President Healthcare Industry Affairs & Strategic Partnerships Email: press@ View original content to download multimedia: SOURCE Inmar Intelligence Sign in to access your portfolio
